NZ597756A - Method for purifying recombinant adamts13 and other proteins and compositions thereof - Google Patents

Method for purifying recombinant adamts13 and other proteins and compositions thereof

Info

Publication number
NZ597756A
NZ597756A NZ597756A NZ59775610A NZ597756A NZ 597756 A NZ597756 A NZ 597756A NZ 597756 A NZ597756 A NZ 597756A NZ 59775610 A NZ59775610 A NZ 59775610A NZ 597756 A NZ597756 A NZ 597756A
Authority
NZ
New Zealand
Prior art keywords
proteins
compositions
purifying recombinant
recombinant adamts13
adamts13
Prior art date
Application number
NZ597756A
Other languages
English (en)
Inventor
Christian Fiedler
Christa Mayer
Meinhard Hasslacher
Artur Mitterer
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Priority to NZ620988A priority Critical patent/NZ620988A/en
Publication of NZ597756A publication Critical patent/NZ597756A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Sustainable Development (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Water Supply & Treatment (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ597756A 2009-07-31 2010-08-02 Method for purifying recombinant adamts13 and other proteins and compositions thereof NZ597756A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ620988A NZ620988A (en) 2009-07-31 2010-08-02 Method for purifying recombinant adamts13 and other proteins and compositions thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23030809P 2009-07-31 2009-07-31
PCT/EP2010/061192 WO2011012726A2 (en) 2009-07-31 2010-08-02 Method for purifying recombinant adamts13 and other proteins and compositions thereof

Publications (1)

Publication Number Publication Date
NZ597756A true NZ597756A (en) 2014-03-28

Family

ID=42588355

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ597756A NZ597756A (en) 2009-07-31 2010-08-02 Method for purifying recombinant adamts13 and other proteins and compositions thereof
NZ620988A NZ620988A (en) 2009-07-31 2010-08-02 Method for purifying recombinant adamts13 and other proteins and compositions thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ620988A NZ620988A (en) 2009-07-31 2010-08-02 Method for purifying recombinant adamts13 and other proteins and compositions thereof

Country Status (22)

Country Link
US (3) US8945895B2 (cg-RX-API-DMAC7.html)
EP (3) EP4299735B1 (cg-RX-API-DMAC7.html)
JP (6) JP5907869B2 (cg-RX-API-DMAC7.html)
KR (7) KR20180087463A (cg-RX-API-DMAC7.html)
CN (3) CN102482660A (cg-RX-API-DMAC7.html)
AU (1) AU2010277491B2 (cg-RX-API-DMAC7.html)
CA (2) CA2769362A1 (cg-RX-API-DMAC7.html)
CO (1) CO6612194A2 (cg-RX-API-DMAC7.html)
DK (1) DK2459715T3 (cg-RX-API-DMAC7.html)
EA (3) EA034292B1 (cg-RX-API-DMAC7.html)
ES (3) ES2763207T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20192303T1 (cg-RX-API-DMAC7.html)
HU (1) HUE046909T2 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN00907A (cg-RX-API-DMAC7.html)
LT (1) LT2459715T (cg-RX-API-DMAC7.html)
MX (2) MX348178B (cg-RX-API-DMAC7.html)
NZ (2) NZ597756A (cg-RX-API-DMAC7.html)
PL (2) PL2459715T3 (cg-RX-API-DMAC7.html)
PT (1) PT2459715T (cg-RX-API-DMAC7.html)
SG (2) SG193855A1 (cg-RX-API-DMAC7.html)
SI (1) SI2459715T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011012726A2 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101576219B1 (ko) 2007-03-14 2015-12-10 다케다 백신즈 인코포레이티드 바이러스 유사 입자 정제
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
EP3456837A3 (en) * 2011-03-14 2019-04-24 Catalent Pharma Solutions, LLC Decorin compositions and use thereof
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9096648B2 (en) 2011-08-19 2015-08-04 Emd Millipore Corporation Methods of reducing level of one or more impurities in a sample during protein purification
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
SI2732020T1 (sl) * 2012-06-21 2017-03-31 Baxalta GmbH Filtracija virusa iz gojišča celične kulture
JOP20130186B1 (ar) * 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CN112126634A (zh) * 2013-01-09 2020-12-25 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US8859252B1 (en) 2014-01-02 2014-10-14 Aerial Biopharma, Llc Prostatic acid phosphatase, compositions comprising the same, and methods for producing and/or purifying the same
JP6609561B2 (ja) * 2014-02-04 2019-11-20 バイオジェン・エムエイ・インコーポレイテッド 翻訳後修飾を濃縮するための、フロースルーモードにおける陽イオン交換クロマトグラフィーの使用
BR112019002194A2 (pt) 2016-08-04 2019-05-21 Baxalta GmbH uso de adamts13 para tratar, melhorar e/ou prevenir a crise vaso-oclusiva na doença falciforme, lesão pulmonar aguda e/ou síndrome da insuficiência respiratória aguda
AU2018357917B2 (en) 2017-10-30 2024-08-01 Takeda Pharmaceutical Company Limited Environmentally compatible detergents for inactivation of lipid-enveloped viruses
WO2019192877A1 (en) * 2018-04-03 2019-10-10 Merck Patent Gmbh Cex chromatography media and low salt elution of target proteins from biopharmaceutical feeds
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
WO2020205928A1 (en) * 2019-04-03 2020-10-08 Genzyme Corporation Continuous production of recombinant proteins
US20220339266A1 (en) 2019-10-04 2022-10-27 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
US11821000B2 (en) * 2020-11-10 2023-11-21 Dionex Corporation Method of separating viral vectors
EP4408876A1 (en) * 2021-09-30 2024-08-07 Ichnos Sciences SA Methods of inactivating viral contaminants with a mixture of solvent and detergent
MX2024010855A (es) 2022-03-07 2024-09-11 Takeda Pharmaceuticals Co Produccion cromatografica de afinidad de productos clinicos de inmunoglobulina g (igg) humana.
TW202400224A (zh) * 2022-05-10 2024-01-01 南韓商綠十字股份有限公司 用於冷凍乾燥血漿蛋白之新穎液體調配物
KR20230159284A (ko) * 2022-05-10 2023-11-21 주식회사 녹십자 혈장 단백질에 대한 신규한 액상 제형물
US20250334572A1 (en) * 2024-04-26 2025-10-30 Waters Technologies Corporation Host cell protein detection using lateral flow devices

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239854A (en) * 1978-04-24 1980-12-16 Sumitomo Chemical Company, Limited Enzyme-immobilization carriers and preparation thereof
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5283182A (en) * 1986-09-17 1994-02-01 Beecham Group Plc Preparation of immobilized hydantoinase stabilized with divalent metal ions
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
FR2681867B1 (fr) 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP0629135B1 (en) 1992-03-02 2000-07-26 Bioeng, Inc. Viral inactivation method
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5578480A (en) * 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
GB9503750D0 (en) * 1995-02-24 1995-04-12 Common Services Agency Thrombin preparation
US5688912A (en) 1995-09-22 1997-11-18 Bayer Corporation Peptide ligands which bind to von willebrand factor
US5831003A (en) 1996-06-28 1998-11-03 Bayer Corporation Peptides which bind to prothrombin and thrombin
US5786458A (en) * 1996-06-28 1998-07-28 Bayer Corporation Selective stabilization of protein during viral inactivation
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6429192B1 (en) 1998-06-10 2002-08-06 Statens Serum Institut Purification process for production of mannan-binding lectin and an MBL medicinal product
US6251860B1 (en) * 1998-07-07 2001-06-26 Suomen Punainen Risti Veripalvelu Pharmaceutical preparations
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
US6451978B2 (en) * 2000-01-21 2002-09-17 Biovitrum Ab Purification of antithrombin-III-α and β
IL136552A (en) * 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
AU2001294218A1 (en) * 2000-10-11 2002-04-22 Kazusa Dna Research Institute Foundation Novel adamts family polypeptide and gene encoding the same
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
CN1230526C (zh) * 2001-02-27 2005-12-07 成都夸常科技有限公司 一种除去作为病毒灭活剂的有机溶剂和/或去污剂的方法
WO2003016492A2 (en) * 2001-08-16 2003-02-27 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
JP2003144154A (ja) * 2001-11-14 2003-05-20 Mitsubishi Pharma Corp 新規なａｄａｍｔｓファミリーポリペプチドおよびそれをコードする遺伝子
EP1470160A2 (en) * 2001-12-05 2004-10-27 Cangene Corporation Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
US20030133829A1 (en) * 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
EP1463942B2 (en) 2001-12-21 2012-06-20 Immunex Corporation Methods for purifying protein
GB0216002D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
JP3944586B2 (ja) * 2002-10-18 2007-07-11 国立循環器病センター総長 フォンビルブランド因子切断酵素の特異的基質および活性測定法
CA2536354C (en) 2003-07-09 2013-08-13 Shionogi & Co., Ltd. Atopic dermatitis inducer
CA2487673C (en) * 2003-12-02 2010-11-02 F. Hoffmann-La Roche Ag Improved method for the recombinant production and purification of protein kinases
GB0405330D0 (en) * 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
EP1740285A4 (en) * 2004-04-13 2007-07-04 Sangart Inc METHOD AND COMPOSITIONS FOR SIMULTANEOUS ISOLATION OF HEMOGLOBIN FROM RED BLOOD BODIES AND INACTIVATION OF VIRUSES
EP1765866B1 (en) 2004-06-07 2014-01-08 Therapure Biopharma Inc. Isolation of plasma or serum proteins
US7270976B2 (en) 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7515392B2 (en) 2004-07-28 2009-04-07 Texas Instruments Incorporated High voltage circuits implemented using low voltage transistors
DE102004044419B4 (de) * 2004-09-14 2010-04-15 Biotest Ag Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie
JP2006083044A (ja) 2004-09-17 2006-03-30 Hitachi Ltd ガラス部材
US20090215699A1 (en) * 2005-01-05 2009-08-27 Foundation For Fatel Rare Diseases Pharmaceutically Active Antiviral Peptides
US20060193966A1 (en) * 2005-02-28 2006-08-31 Shaowen Wu Multi-anion treated soy proteins and methods for preparation thereof
AU2006257073B2 (en) 2005-06-17 2011-08-04 Children's Medical Center Corporation ADAMTS13-comprising compositions having thrombolytic activity
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
US7506514B2 (en) 2005-06-30 2009-03-24 United Technologies Corporation Augmentor fuel conduit bushing
WO2007065691A2 (en) * 2005-12-07 2007-06-14 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
JP5067917B2 (ja) 2005-12-28 2012-11-07 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の分離精製方法
JP5221333B2 (ja) 2006-02-16 2013-06-26 三菱化学メディエンス株式会社 意識障害患者における病態の検出方法及び検出用キット
US7468258B2 (en) 2006-03-07 2008-12-23 Wake Forest University Health Sciences Self-quenching homofluorophore compositions for detecting enzyme activity
WO2008057074A1 (en) * 2006-11-06 2008-05-15 Millipore Corporation Method of flow-through chromatography
EP1958626B1 (en) 2007-02-13 2014-07-23 Ajinomoto Co., Inc. Method for inactivating viruses by addition of slightly acidic arginine
JP5254973B2 (ja) 2007-06-22 2013-08-07 一般財団法人化学及血清療法研究所 新規ａｄａｍｔｓ−１３改変体
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
KR101293504B1 (ko) 2007-07-11 2013-08-07 노보 노르디스크 에이/에스 혼합형 또는 다중형 수지를 사용하는 인자 ｖⅰⅰⅰ의 정제
US20110097318A1 (en) * 2007-08-31 2011-04-28 Amgen Inc. Solid-State Protein Formulation
US20090130714A1 (en) * 2007-09-24 2009-05-21 Reliance Life Sciences Pvt.Ltd. Process for purifying recombinanat tissue plasminogen activator (TPA)
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof

Also Published As

Publication number Publication date
JP2016222724A (ja) 2016-12-28
KR101883610B1 (ko) 2018-07-30
ES3000382T3 (en) 2025-02-28
ES2763207T3 (es) 2020-05-27
HRP20192303T1 (hr) 2020-10-02
AU2010277491B2 (en) 2015-12-17
BR112012002140A2 (pt) 2015-09-15
LT2459715T (lt) 2020-01-10
JP6216930B2 (ja) 2017-10-25
IN2012DN00907A (cg-RX-API-DMAC7.html) 2015-04-03
EP4299735A2 (en) 2024-01-03
JP2018203781A (ja) 2018-12-27
KR20180087463A (ko) 2018-08-01
MX348178B (es) 2017-05-29
KR20190122272A (ko) 2019-10-29
HUE046909T2 (hu) 2020-04-28
AU2010277491A1 (en) 2012-02-16
CN102482660A (zh) 2012-05-30
EA023783B1 (ru) 2016-07-29
DK2459715T3 (da) 2020-01-06
NZ620988A (en) 2015-07-31
SI2459715T1 (sl) 2020-01-31
KR20220066435A (ko) 2022-05-24
US20230242897A1 (en) 2023-08-03
PL3211077T3 (pl) 2025-04-14
SG178175A1 (en) 2012-03-29
EP2459715B1 (en) 2019-10-02
US11661593B2 (en) 2023-05-30
EA201270214A1 (ru) 2012-08-30
EA201992487A1 (ru) 2020-05-31
JP2022171925A (ja) 2022-11-11
SG193855A1 (en) 2013-10-30
PL2459715T3 (pl) 2020-04-30
US20150104849A1 (en) 2015-04-16
AU2010277491A2 (en) 2012-06-21
CN107988192A (zh) 2018-05-04
CA2916508A1 (en) 2011-02-03
MX2012001263A (es) 2012-05-22
EP2459715A2 (en) 2012-06-06
WO2011012726A2 (en) 2011-02-03
US20110081700A1 (en) 2011-04-07
EP4299735A3 (en) 2024-04-24
EA034292B1 (ru) 2020-01-24
CO6612194A2 (es) 2013-02-01
PT2459715T (pt) 2020-01-09
JP2021004265A (ja) 2021-01-14
KR20120053013A (ko) 2012-05-24
EP3211077A1 (en) 2017-08-30
US8945895B2 (en) 2015-02-03
WO2011012726A3 (en) 2011-03-31
KR20170096061A (ko) 2017-08-23
JP5907869B2 (ja) 2016-04-26
CN107267490A (zh) 2017-10-20
JP2015147815A (ja) 2015-08-20
JP2013500711A (ja) 2013-01-10
KR20230170815A (ko) 2023-12-19
CA2769362A1 (en) 2011-02-03
KR101769634B1 (ko) 2017-08-18
US12492390B2 (en) 2025-12-09
KR20200146042A (ko) 2020-12-31
EP4299735B1 (en) 2025-05-21
EP3211077B1 (en) 2024-09-25
EA201500952A1 (ru) 2016-05-31
ES3039686T3 (en) 2025-10-23

Similar Documents

Publication Publication Date Title
NZ597756A (en) Method for purifying recombinant adamts13 and other proteins and compositions thereof
IN2012DN00801A (cg-RX-API-DMAC7.html)
IN2012DN03911A (cg-RX-API-DMAC7.html)
ZA200904482B (en) Polyelectrolyte precipitation and purification of antibodies
EA201070987A1 (ru) Очищенные гибридные белки иммуноглобулина и способы их очищения
EP2554669A4 (en) NEW ANTIBODY WITH ITS INTRODUCED MODIFICATION CENTER AND ANTIBODY FRAGMENT
EP2796469A3 (en) Novel compositions and methods for treating ige-mediated disorders
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
WO2013138793A3 (en) Affinity reagants for protein purification
WO2011047087A3 (en) Protein detection via nanoreporters
HK1206756A1 (en) Modulated lysine variant species compositions and methods for producing and using the same
WO2009105670A3 (en) Substrates for multiplexed assays and uses thereof
WO2012009644A3 (en) Methods to identify synthetic and natural rna elements that enhance protein translation
MX2012002565A (es) Purificacion de proteina mejorada a traves de una elucion de proteina a modificada.
SG196839A1 (en) Antibodies against fcrn and use thereof
UA101944C2 (ru) Композиции и способы применения для антител dickopf-1
WO2008085962A3 (en) Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
PE20120170A1 (es) Variantes de union a anti-albumina de suero mejoradas
WO2007120638A3 (en) Methods and compositions for modulating glycosylation
ATE533838T1 (de) Verfahren zur verbesserten einführung von dna in bakterienzellen
WO2011028883A3 (en) Metalloproteinase 9 and metalloproteinase 2 binding proteins
MX341064B (es) Variantes de la familia il-1.
MX2014011614A (es) Fragmentos y proteinas nutritivas con fenilalanina baja o nula y metodos.
GB201014028D0 (en) In-situ reagent
WO2008054514A3 (en) Differential expression profiling analysis of cell culture phenotypes and the uses thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 02 AUG 2017 BY COMPUTER PACKAGES INC

Effective date: 20140828

ASS Change of ownership

Owner name: BAXALTA GMBH, CH

Effective date: 20160414

Owner name: BAXALTA INC, US

Effective date: 20160414

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2018 BY COMPUTER PACKAGES INC

Effective date: 20170718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2019 BY ANAQUA SERVICES

Effective date: 20180719

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2020 BY ANAQUA SERVICES

Effective date: 20190722

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2021 BY ANAQUA SERVICES

Effective date: 20200721

ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20210330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2022 BY ANAQUA SERVICES

Effective date: 20210720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2023 BY ANAQUA SERVICES

Effective date: 20220721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2024 BY ANAQUA SERVICES

Effective date: 20230720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2025 BY ANAQUA SERVICES

Effective date: 20240723

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2026 BY ANAQUA SERVICES

Effective date: 20250723